Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average - Here's Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.80 and traded as low as $0.68. Karyopharm Therapeutics shares last traded at $0.70, with a volume of 433,181 shares traded.

Analyst Ratings Changes

Several brokerages have issued reports on KPTI. Piper Sandler raised their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 6th. StockNews.com cut Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Trading Up 1.7 %

The stock has a market cap of $88.32 million, a P/E ratio of -0.61 and a beta of 0.07. The company has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.80.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same period last year, the company earned ($0.30) EPS. As a group, equities analysts forecast that Karyopharm Therapeutics Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock worth $1,125,000 after acquiring an additional 43,856 shares during the period. FMR LLC grew its holdings in Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company's stock worth $307,000 after acquiring an additional 76,510 shares during the period. GSA Capital Partners LLP grew its holdings in Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock worth $1,474,000 after acquiring an additional 792,283 shares during the period. Exchange Traded Concepts LLC boosted its position in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock worth $182,000 after purchasing an additional 56,613 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new position in Karyopharm Therapeutics during the second quarter worth approximately $31,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).